What Is the CJC-1295 (No DAC)/Ipamorelin Formulation?
This formulation combines two growth hormone modulating peptides that act through different receptor pathways.
CJC-1295 (No DAC), also referred to as MOD-GRF (1-29), is a modified GHRH analog designed to drive a short, pulse like GH release rather than prolonged elevation
Ipamorelin is a growth hormone secretagogue (GHS) that acts through the ghrelin receptor pathway
Because the pathways differ, this pairing is commonly discussed in GH axis research as a way to amplify natural GH pulses while keeping secretion patterns closer to endogenous pulsatility.
Mechanisms of Action
Stimulate the anterior pituitary via GHRH receptor binding (CJC-1295 No DAC) to trigger release of stored GH
Amplify GH pulse amplitude when a GHRH analog is paired with a GHS such as Ipamorelin
Produce a quick GH spike due to the short half life profile of MOD-GRF (1-29), avoiding sustained GH elevation seen with DAC based analogs
Support a more physiologic secretion pattern by emphasizing pulses rather than prolonged elevation
Benefits
Lean mass support and body composition related endpoints through GH pulse amplification
Fat metabolism support signals via GH mediated substrate utilization effects
Recovery and tissue repair related signaling, including connective tissue and joint support endpoints
Collagen synthesis related signals that may support skin elasticity and wound healing models
Metabolic health endpoints, including glucose regulation and energy balance related measures
Dosing
Strength | Dose |
|---|---|
Low | 150 mcg each per day (300 mcg total per day) |
Medium | 250 mcg each per day (500 mcg total per day) |
High | 500 mcg each per day (1000 mcg total per day) |
Growth hormone secretagogues are commonly cycled in research contexts at 8 to 12 weeks on and 2 to 4 weeks off, and often 5 to 6 days on with 1 to 2 days off, although some designs use daily protocols.
Safety Profile
This formulation approach is often described as generally well tolerated, with potential observations including:
Mild transient flushing
Temporary injection site irritation such as mild redness or swelling
Short lived GH related adjustment effects such as temporary water retention or numbness that resolve as the model adapts
Because CJC-1295 (No DAC) is designed to mimic pulsatile secretion, it is commonly framed as having a lower desensitization risk than long acting GH analog approaches.
Stacking
Recovery Stack:
CJC-1295 (No DAC) + Ipamorelin
GLOW or KLOW
Glutathione
Fat Loss Stack
CJC-1295 (No DAC) + Ipamorelin
Retatrutide
L-Carnitine
SLU-PP-332
Sleep Stack
CJC-1295/Ipamorelin
DSIP
Epithalon and/or Pinealon
Muscle Growth Stack
CJC-1295 (No DAC) + Ipamorelin
IGF-1 LR3 (Advanced users only)
Disclaimer: The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. All compounds referenced are not for human consumption.
